Enhanced breast cancer therapy with nsPEFs and low concentrations of   gemcitabine

doi:10.1186/s12935-014-0098-4

CORC > 北京大学 > 工学院

	Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine
	Wu, Shan ; Guo, Jinsong ; Wei, Wendong ; Zhang, Jue ; Fang, Jing ; Beebe, Stephen J.
刊名	cancer cell international
	2014
关键词	Breast cancer MCF-7 MDA-MB-231 Nanosecond pulsed electric fields (nsPEFs) Non-thermal Gemcitabine Synergism Clonogenics Apoptosis Necrosis (necroptosis) PULSED ELECTRIC-FIELDS PROGRAMMED NECROSIS OVARIAN-CANCER GROWTH-RATE HUMAN-CELLS IN-VITRO NANOSECOND APOPTOSIS MECHANISMS CARCINOMA
DOI	10.1186/s12935-014-0098-4
英文摘要	Background: Chemotherapy either before or after surgery is a common breast cancer treatment. Long-term, high dose treatments with chemotherapeutic drugs often result in undesirable side effects, frequent recurrences and resistances to therapy. Methods: The anti-cancer drug, gemcitabine (GEM) was used in combination with pulse power technology with nanosecond pulsed electric fields (nsPEFs) for treatment of human breast cancer cells in vitro. Two strategies include sensitizing mammary tumor cells with GEM before nsPEF treatment or sensitizing cells with nsPEFs before GEM treatment. Breast cancer cell lines MCF-7 and MDA-MB-231 were treated with 250 65 ns-duration pulses and electric fields of 15, 20 or 25 kV/cm before or after treatment with 0.38 mu M GEM. Results: Both cell lines exhibited robust synergism for loss of cell viability 24 h and 48 h after treatment; treatment with GEM before nsPEFs was the preferred order. In clonogenic assays, only MDA-MB-231 cells showed synergism; again GEM before nsPEFs was the preferred order. In apoptosis/necrosis assays with Annexin-V-FITC/propidium iodide 2 h after treatment, both cell lines exhibited apoptosis as a major cell death mechanism, but only MDA-MB-231 cells exhibited modest synergism. However, unlike viability assays, nsPEF treatment before GEM was preferred. MDA-MB-231 cells exhibited much greater levels of necrosis then in MCF-7 cells, which were very low. Synergy was robust and greater when nsPEF treatment was before GEM. Conclusions: Combination treatments with low GEM concentrations and modest nsPEFs provide enhanced cytotoxicity in two breast cancer cell lines. The treatment order is flexible, although long-term survival and short-term cell death analyses indicated different treatment order preferences. Based on synergism, apoptosis mechanisms for both agents were more similar in MCF-7 than in MDA-MB-231 cells. In contrast, necrosis mechanisms for the two agents were distinctly different in MDA-MB-231, but too low to reliably evaluate in MCF-7 cells. While disease mechanisms in the two cell lines are different based on the differential synergistic response to treatments, combination treatment with GEM and nsPEFs should provide an advantageous therapy for breast cancer ablation in vivo.; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000346202200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701 ; Oncology; SCI(E); PubMed; 2; ARTICLE; sbeebe@odu.edu; 1; 98; 14
语种	英语
内容类型	期刊论文
源URL	[http://ir.pku.edu.cn/handle/20.500.11897/153804]
专题	工学院
推荐引用方式 GB/T 7714	Wu, Shan,Guo, Jinsong,Wei, Wendong,et al. Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine[J]. cancer cell international,2014.
APA	Wu, Shan,Guo, Jinsong,Wei, Wendong,Zhang, Jue,Fang, Jing,&Beebe, Stephen J..(2014).Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine.cancer cell international.
MLA	Wu, Shan,et al."Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine".cancer cell international (2014).